In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.
about
The treatment of Legionnaires' disease.In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumoniaIn vitro activity of Ro 23-9424 against clinical isolates of Legionella speciesIn vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species.Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages.Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens.In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophilaActivity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumoniaIn vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groupsIn vitro activity of RP 74501-RP 74502, a novel streptogramin antimicrobial mixture, against clinical isolates of Legionella speciesIn vitro antibacterial activities of PD 138312 and PD 140248, new fluoronaphthyridines with outstanding gram-positive potency.Therapeutic advances of new fluoroquinolones.In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.In vitro activity of ABT-773 against Legionella pneumophila, its pharmacokinetics in guinea pigs, and its use to treat guinea pigs with L. pneumophila pneumonia.Simplified quantitative assay system for measuring activities of drugs against intracellular Legionella pneumophila.Susceptibilities of Legionella spp. to newer antimicrobials in vitro.Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila.Use of the microbial growth curve in postantibiotic effect studies of Legionella pneumophila.Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia.Evaluation of a human monocytic cell line THP-1 model for assay of the intracellular activities of antimicrobial agents against Legionella pneumophila.The association of antibiotic treatment regimen and hospital mortality in patients hospitalized with Legionella pneumonia.In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria
P2860
Q33686303-0C278A7C-3988-42DD-95A6-E405B1FBC2AFQ33744843-8C612BA5-056E-4ABC-9BFF-F17EBCA6BC7DQ33746330-31C40418-BAFD-4BA3-B691-5EC9AF296A97Q33748397-20BE1EF6-D070-4F5C-8D3E-0CD20A534A7FQ33748466-55FB8B67-C1BC-46FA-93D5-AECC05D82C10Q34719806-225B2ABB-656D-4D9F-ACFD-7422A6550BAAQ34728521-D6D23CE4-BC9B-40F8-89ED-BC451CE79BDFQ35116792-66486C83-B374-4C12-AAD6-3156B644B523Q35122254-CD5FE073-F958-4EE4-9768-B7DF636596E4Q35758905-6E6672C1-6772-4725-8835-9C7B3F141124Q35812980-56F5A1F4-AB41-4E53-87A1-F80804C6CBC0Q35904010-3704DB75-8D3C-4754-B229-190A60574F24Q36181167-E42D6D7D-5430-413F-B87D-6EC2C525592EQ39469546-404DFD41-E07B-4FF9-BB94-351C4E4D2D7AQ39477931-1B855534-D4FB-41AE-8FCF-0834028AC95FQ39478420-79BD0B66-C1DE-4E47-9F2C-7F56F6C2F63AQ39553788-19DB00A6-04E9-49BE-841D-D2E1F5515CE7Q39557831-393C3954-80CA-401D-904B-93574CE7276AQ39559639-C685D2F4-DA50-48ED-82CE-8123DADB4691Q39731821-E7818884-C4DB-4D89-BFB3-9B5D56AB7B63Q39740470-100BC866-C0A1-4414-8E3E-4FEEFAA75E4EQ40851098-6716CEDA-DD81-4EE0-B75C-DA1B5D01AAEEQ41461523-AB0282D7-CEA4-4D4A-B2FF-2DC71D6189F1Q41668866-15BBAF07-C17A-4C9F-91CD-BF15BABE0BE6
P2860
In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.
description
1990 nî lūn-bûn
@nan
1990 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
In vitro activity of sparfloxa ...... with L. pneumophila pneumonia.
@ast
In vitro activity of sparfloxa ...... with L. pneumophila pneumonia.
@en
type
label
In vitro activity of sparfloxa ...... with L. pneumophila pneumonia.
@ast
In vitro activity of sparfloxa ...... with L. pneumophila pneumonia.
@en
prefLabel
In vitro activity of sparfloxa ...... with L. pneumophila pneumonia.
@ast
In vitro activity of sparfloxa ...... with L. pneumophila pneumonia.
@en
P2093
P2860
P356
P1476
In vitro activity of sparfloxa ...... with L. pneumophila pneumonia.
@en
P2093
J Weidenfeld
M A Edelstein
P H Edelstein
P2860
P304
P356
10.1128/AAC.34.11.2122
P407
P577
1990-11-01T00:00:00Z